CALC — CalciMedica, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1534133 ·
Last close
$1.22
Market Cap
$8.41M
52W High
$36.00
52W Low
$1.00
ADV30
75,897
Next earnings
—
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -4,751,000 -1,674,000 14,294,000 4,574,000 10,067,000
Jun 2026 0 — -4,012,000 -7,652,000 19,503,000 18,617,000 13,990,000
Mar 2026 0 — -5,611,000 4,976,000 8,609,000 8,164,000 9,713,000
Dec 2025 0 — -4,385,000 -10,760,000 13,591,000 11,520,000 20,232,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-18,191,000
Investing CF
$-453,000
Financing CF
$17,748,000
CapEx
$-28,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.51
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-193,676,000
Inventory
—
Receivables
—
ST Investments
$9,194,000
EBIT TTM
$-13,784,000
Pretax Income TTM
$-15,110,000
Interest Exp TTM
$1,326,000
Analysts
2

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -23,121,000 -29,562,000 13,591,000 20,232,000 -6,641,000 -21,178,000
Dec 2024 0 -24,204,000 -13,700,000 19,794,000 5,384,000 14,410,000 -21,146,000
Dec 2023 0 -38,075,000 -34,357,000 12,185,000 4,028,000 8,157,000 -25,730,000
Dec 2022 0 -14,193,000 -7,824,000 3,349,000 12,582,000 -9,233,000 -11,757,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-21,240,000
OpCashFlow TTM
—
Assets (Latest)
$19,503,000
Forward EPS
$-1.63

Peers — same industry

TickerNameMarket CapLastDaily %
DARE Dare Bioscience, Inc. $8.44M $0.43 —
VTGN Vistagen Therapeutics, Inc. $8.34M $0.19 —
KYNB KYNTRA BIO, INC. $8.26M $2.04 —
PHIO Phio Pharmaceuticals Corp. $8.57M $0.72 —
MTVA MetaVia Inc. $8.24M $1.25 —

News headlines (Yahoo Finance, 1h cache)

What Makes CalciMedica Inc. (CALC) a New Buy Stock
2026-11-12 16:00 · Yahoo
CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
2026-11-10 12:00 · Yahoo
CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-03 13:00 · Yahoo
CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 11:00 · Yahoo
CalciMedica stock gains 6% as pulmonary hypertension progress offsets Q2 earnings miss
2026-08-11 14:11 · Yahoo
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
2026-07-29 11:00 · Yahoo
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
2026-06-24 11:00 · Yahoo
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
2026-06-24 11:01 · Yahoo
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
2026-05-12 11:00 · Yahoo
CalciMedica Announces One-for-Five Reverse Stock Split
2026-08-27 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.